As Test Volumes Grow, Foundation Medicine Welcomes FDA Regulation of LDTs | GenomeWeb

NEW YORK (GenomeWeb) – Sales of Foundation Medicine's next-generation sequencing-based tumor profiling tests are growing both among its clinical and pharmaceutical customers, the company said this week, leading to a 145 percent growth in its second quarter revenues to $14.5 million from $5.9 million in Q2 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.